The short answer
A bleeding interaction between Panax ginseng and dalteparin is unconfirmed. Human studies of tested ginseng products found little or no effect on platelet and clotting measurements, including when combined with aspirin.
What this answer covers
Oral Panax ginseng products with subcutaneous dalteparin sodium; American ginseng, red/white preparations and mixed formulas are not interchangeable.
- Supplement or preparation
- Panax ginseng
- Medication ingredient
- dalteparin
The human findings are mostly null
A randomized study of Panax ginseng alone and with aspirin found no clinically important overall hemostatic effect or significant bleeding. One participant showed inhibition on one platelet stimulus. A separate small commercial-product study found no platelet-function effect.
Dalteparin was not the study treatment
Neither trial measured bleeding during dalteparin treatment. Aspirin and dalteparin act differently, and a small healthy-volunteer study cannot exclude uncommon complications in a sick or surgical patient.
Do not transfer results across ginseng products
The species, processing and extract composition should be checked. Studies and reports involving another Panax species or a blend do not establish a one-way effect for this exact product. The original abstracts also leave some formulation details unresolved.
Review rather than assume a dosing rule
Tell the dalteparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed dalteparin yourself. No universal avoidance recommendation or protective interval follows from the reviewed exact-product evidence.
Evidence and practical considerations
Side effects & toxicity
No direct dalteparin clinical bleeding evidence; indirect original human findings include null results and cannot establish this broad increased-risk claim.
- Exact scope
- Oral Panax ginseng products with subcutaneous dalteparin sodium; American ginseng, red/white preparations and mixed formulas are not interchangeable. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers; 24 evaluable for Angelica and 23 for Panax ginseng.
No clinically relevant overall effect on platelet/coagulation function, no added aspirin platelet inhibition, and no significant bleeding manifestations. A few participants had inhibition on one platelet stimulus.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
25 volunteers recruited per herb; product standardization incompletely described in abstract. Aspirin is not dalteparin. Small short study cannot exclude rare bleeding.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten adult volunteers.
No PFA-100 platelet-function effect from any tested herb; aspirin control inhibited function.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Only ten volunteers and a laboratory platelet test. Not clinical bleeding surveillance in dalteparin recipients; original experimental component used, not the accompanying review.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact dalteparin article with independently checked product label and explicit limits on indirect supplement evidence. | |
| Research summary published |
Article revision: f7a12cd2e33e27b3
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.